sample	drug	gatkscore	depth	readsratio	gene	diplotype	cHGVS	pHGVS	zyg	guide	advice	effect	suggest	ref_guide	drugid	rsID	location
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	阿托伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs2306283	chr22:42130692:G>A
Test	艾拉戈利	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het			Poor Function;Possible Decreased Function;Decreased Function	&quot;Results in higher systemic concentrations.&quot;	FDA PGx Association	PA166182348	rs2306283	chr22:42130692:G>A
Test	艾拉戈利	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het			Poor Function;Possible Decreased Function;Decreased Function	&quot;Results in higher systemic concentrations.&quot;	FDA PGx Association	PA166182348	rs2306283	chr22:42130692:G>A
Test	艾拉戈利	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het			Poor Function;Possible Decreased Function;Decreased Function	&quot;Results in higher systemic concentrations.&quot;	FDA PGx Association	PA166182348	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	氟伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		CYP2C9: n/a;SLCO1B1: Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;40mg per day. CYP2C9 genotype result is not available.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	洛伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	匹伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;1mg. If dose &gt;2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	普伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	瑞舒伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		ABCG2: Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects;SLCO1B1: Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses &gt;20mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*15	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*14/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*20	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*24	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*25	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*27	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*28	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*29	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*30	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*31	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*32	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*33	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*37	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*39	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*42	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*43	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*15/*44	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*20/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*24/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*25/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*27/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*28/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*29/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*30/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*31/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*32/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*33/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*37/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*39/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*42/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*43/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*46	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
Test	辛伐他汀	513.64	22,17	0.44	SLCO1B1	*44/*47	c.388A>G	p.Asn130Asp	Het		SLCO1B1: Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy	Poor Function;Possible Decreased Function;Decreased Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to &lt;20mg/day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs2306283	chr22:42130692:G>A
